Document is current
Any future updates will be listed below
-
Authors
Cui, Yuqing
Feng, Xiaomeng
Shao, Ruonan
Zhang, Lining
Li, Xueyuan
Lin, Qingsong
Wang, Jieru
Liu, Li
Pan, Ling
Zhen, Sisi
Fan, Yuping
Zhang, Tingting
Mi, Yingchang
Xiao, Zhijian
Jiang, Erlie
Han, Mingzhe
Wang, Jianxiang
Chen, Xin
Feng, Sizhou https://orcid.org/0000-0003-2768-6690
-
Funding
Funding for this research was provided by:
Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0510400)
the Fundamental Research Funds for the Central Universities, Peking Union Medical College (3332024077)
Beijing Xisike Clinical Oncology Research Foundation (Y-SYBLD2022RWR-0017)
Tianjin Municipal Science and Technology Commission Grant (25ZXRKSY00040)
Tianjin Municipal Science and Technology Commission Grant (25ZXRKSY00040)
National Natural Sciences Foundation of China (82470208)
Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2021-I2M-1-017)
National Key R&D Program of China (2024YFC2510500)
Research Fund for Clinical Application of Amphotericin B Antifungal Agents (KC2024-JX-0092-1)
- License Information
-
More Information
Article History
Received: 23 November 2025
Accepted: 5 July 2026
First Online: 10 July 2026
Declarations
:
: This study was approved by the Institutional Review Board (IRB) of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and conducted in accordance with the Declaration of Helsinki (No. IIT2022071 - EC − 1). Due to the retrospective nature of this study, the requirement for individual written informed consent was waived.
: The authors declare no competing interests.
